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RNA interferenceAmong the multiple G protein–coupled receptor (GPCR) endocytic pathways, clathrin-mediated endocytosis
(CME) and caveolar endocytosis are more extensively characterized than other endocytic pathways. A number
of endocytic inhibitors have been used to block CME; however, systemic studies to determine the selectivity of
these inhibitors are needed. Clathrin heavy chain or caveolin1-knockdown cells have been employed to deter-
mine the speciﬁcity of various chemical andmolecular biological tools for CMEand caveolar endocytosis. Sucrose,
concanavalin A, and dominant negative mutants of dynamin blocked other endocytic pathways, in addition to
CME. In particular, concanavalin A nonspeciﬁcally interfered with the signaling of several GPCRs tested in the
study. Decreased pH, monodansylcadaverine, and dominant negative mutants of epsin were more speciﬁc for
CME than other treatments were. A recently introduced CME inhibitor, Pitstop2™, showed only marginal selec-
tivity for CME and interfered with receptor expression on the cell surface. Blockade of receptor endocytosis by
epsinmutants and knockdown of the clathrin heavy chain enhanced the β2AR-mediated ERK activation. Overall,
our studies show that previous experimental results should be interpreted with discretion if they included the
use of endocytic inhibitors that were previously thought to be CME-selective. In addition, our study shows that
endocytosis of β2 adrenoceptor through clathrin-mediated pathway has negative effects on ERK activation.
© 2015 Elsevier B.V. All rights reserved.1. Introduction
Signal transduction and intracellular trafﬁcking of G protein–coupled
receptors (GPCRs) occur simultaneously in response to agonist stimula-
tion. In addition, receptor endocytosis and subsequent recycling is inti-
mately related to the regulation of receptor function [1,2]. Receptor
endocytosis can be broadly categorized into clathrin-mediated and
clathrin-independent processes. Clathrin-mediated endocytosis (CME)
is characterized by the formation of a partially invaginated membrane
structure with a clathrin-coated cytoplasmic surface, followed by the
pinching off of the invaginated clathrin-coated vesicles with the help of
dynamin [3–5]. This pathway requires the coordinated interplay of a
number of adaptor and accessory molecules, including the adaptor pro-
tein (AP) 2 complex, amphiphysin, and dynamin, as well as G protein–
coupled receptor kinases (GRK)/β-arrestins that phosphorylate and
connect receptors to clathrin and the AP2 complex [6–9].Caveolae are ﬂask-shaped invaginations of the plasma membrane
that primarily comprises caveolin1 (Cav1) [10,11]. Caveolae act as
major cellular components that mediate receptor signaling [11], as
well as clathrin-independent, raft-dependent endocytosis [12,13].
Caveolar endocytosis is sensitive to cholesterol depletion and is
dynamin-dependent, similar to CME.
A number of molecular biological tools and pharmacological agents
have been used to selectively inhibit CME [6]. Molecular biological
approaches include the use of dominant-negative mutants and RNA
interference technology to compete with and downregulate the expres-
sion of endogenous proteins involved in CME. Pharmacological agents
are more convenient than molecular biological approaches, because
they inﬂuence the entire cell population equally without concerns
of transfection efﬁciency. However, nonspeciﬁc effects are a major
drawback of pharmacological agents [6]. Thus, caution is needed
when using pharmacological inhibitors whose selectivity remains
to be clariﬁed.
In this study, we examined the speciﬁcity of molecular biological
manipulations and pharmacological inhibitors that are frequently used
to block clathrin- and caveolae-dependent endocytic pathways. To de-
termine the selectivity of the molecular biological and pharmacological
2102 S. Guo et al. / Biochimica et Biophysica Acta 1848 (2015) 2101–2110agents used to inhibit CME, endogenous clathrin heavy chain (CHC) or
Cav1 was knocked down. We used the β2-adrenoceptor (β2AR) and
the dopamine D2 receptor (D2R) as model receptors to assess receptor
endocytosis. Much of the current knowledge concerning the molecular
basis of GPCR endocytosis is derived from studies on β2AR [7]. In addi-
tion, D2R is known to internalize in a GRK/β-arrestin-dependent
manner [14] via the clathrin- and caveolae-mediated endocytic path-
way [15,16].
Our results indicate that some of the pharmacological agents used to
block CME can also inhibit other endocytic pathways. Thus, the func-
tional meaning of previously reported experimental results needs to
be reinterpreted if non-selective agents were employed in studies. In
addition, these results will provide useful information to select the cor-
rect pharmacological agents and their dosages to achieve selective
blockade of CME pathways.Clathrin
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Fig. 1.Effects of CHC andCav1knockdownonβ2AR internalization. (A) (Upperpanel)HEK-293 c
tagged with the green ﬂuorescent protein at the C-terminus (β2AR-GFP). After 24 h, cells were t
control knockdown (Con-KD) and CHC-KD cells were blotted with antibodies targeting CHC an
by densitometry. Data represent results from three independent experiments with similar out
After 24 h, cells were treated with vehicle or 1 μM ISO for 20min. (Lower panel) Cell lysates we
Lysates were blotted with antibodies targeting Cav1 and actin. Approximately 90% of cellular C
quantiﬁed by densitometry. Data represent results from two independent experiments with si2. Materials and methods
2.1. Reagents
Dopamine (DA), isoproterenol (ISO), sucrose, angiotensin II
(AgII), monodansylcadaverine (MDC), concanavalin A (ConA),
methyl-β-cyclodextrin (MβCD), forskolin, and antibodies against
actin were obtained from Sigma Aldrich Chemical Co. (St. Louis,
MO, USA). [3H]-Sulpiride (84 Ci/mmol) and [3H]-CGP-12177
(41.7 Ci/mmol) were purchased from Perkin Elmer Life Sciences
(Boston, MA, USA). Antibodies against CHC were purchased from
BD Biosciences (San Jose, CA, USA). Antibodies targeting Cav1
were purchased from BD Transduction Laboratories (Franklin
Lakes, NJ, USA). Antibodies targeting the HA epitope and GRK2
were obtained from Santa Cruz Biotechnology (Santa Cruz, CA,B
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av1 was knocked down by stable expression of shRNA, and the degree of knockdown was
milar outcomes.
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Probes (Invitrogen, Carlsbad, CA, USA). Pitstop2™was synthesized
according to the protocols described below. The monoclonal mouseMock
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Fig. 2. Evaluation of endocytic inhibitor selectivity toward CME and caveolar endocytosis. (A) E
zation of β2AR. Con-KD, CHC-KD, and Cav1-KD cells expressing β2AR were transfected with 4 μ
dish, and receptor internalization was determined. Cells were treated with 1 μM isoproterenol
the Con-KD/mock group (n = 6). Receptor expression levels were approximately 0.9 pmol/m
CHC-KD, and Cav1-KD cells expressing β2AR were treated with 1, 2, 3, and 5 mM MβCD for 3
group. **: p b 0.01 and ***: p b 0.001 compared to the each vehicle group (n = 6). Receptor
458) and MβCD on the internalization of β2AR. Con-KD, CHC-KD, and Cav1-KD cells expressin
100 mm culture dish and/or were treated with 3.5 mM MβCD for 30 min. ***: p b 0.001 com
group. $$$: p b 0.001 compared to Con-KD/mock/MβCD group or Con-KD/Epsin (204–458)/veh
zation. Con-KD and CHC-KD cells expressing β2AR (0.8–0.9 pmol/mg protein) were transfected
Cav1-shRNA in PLKO.1. Cells were treated with 1 μM ISO for 20 min. ***: p b 0.001 compared t
experimental groups were blotted with antibodies against Cav1, CHC, and actin. (E) Role of G
β2AR or β2AR-GRK2-KO (0.7–0.9 pmol/mg protein) were treated with 1 μM ISO for 20min. **:
WT-β2ARorβ2AR-GRK2-KO (0.7–0.9 pmol/mgprotein)were treatedwith 3mMMβCD for 30m
to the each vehicle-treated group. ###: p b 0.001 compared to WT-β2AR/vehicle-treated groupanti-phospho-ERK antibody and polyclonal goat anti-ERK2 were
purchased from Sigma, Santa Cruz Biotechnology, or Cell Signaling
Technology (Beverly, MA, USA).B β2AR
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icle group (n= 3). (D) Effects of combined CHC and Cav1 knockdown on β2AR internali-
with 4 μg PLKO.1 vector per 100mm culture dish. CHC-KD cells were transfectedwith 4 μg
o Con-KD group. ##: p b 0.01 compared to CHC-KD group (n = 3). Cell lysates from three
RK2-mediated phosphorylation on β2AR CME. Con-KD and CHC-KD cells expressing WT-
p b 0.01, ###: p b 0.001 compared to Con-KD/WT-β2AR group (n= 3). (F) Cells expressing
in, followedby treatmentwith 1 μMISO for 20min. **: p b 0.01 and ***:p b 0.001 compared
(n = 3).
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Human embryonic kidney cells (HEK-293) and COS-7 cells were
obtained from the American Type Culture Collection (Rockville,
MD, USA) and maintained in minimum essential medium (MEM)
and Dulbecco's modiﬁed Eagle's medium (DMEM), respectively,
supplemented with 10% fetal bovine serum, 100 U/ml penicillin,
and 100 μg/ml streptomycin in a humidiﬁed atmosphere containing
5% CO2.2.3. DNA constructs
The mammalian expression constructs for the human D2R (short
alternatively spliced form), D3 receptor (D3R), D4 receptor (D4R),
β2AR, and GRK2 have been described previously [5,14]. FLAG-tagged
human angiotensin II type 1 receptor (AT1R)was prepared by polymer-
ase chain reaction. A mutant of β2AR (β2AR-GRK2-KO), in which the
consensus phosphorylation sites for GRK2 (T360, S364, S396, S401,
S407, S411) [17] were mutated, was prepared via site-directed muta-
genesis. A glycosylation mutant of D2R (D2R-GlyX, N5Q/N17Q/N23Q)
was also prepared by site-directed mutagenesis. GFP tagged ERK was
described previously [18]. Small hairpin RNA (shRNA) targeting the
CHC and Cav1 were described previously [19,20]. Dominant negative
mutants of dynamin2 (K44A-Dyn2) and epsin (epsin [204–458]) wereA
Vehicle
Sucrose
ConA
%
 In
te
rn
al
iz
at
io
n
Con-KD CHC-KD
***
###
**
β2AR
C D4R
0
5
10
15
20
25
30
###
**
***
Cav1-KD
%
In
te
rn
al
iz
at
io
n
0
5
10
15
20
*** ***
**
Vehicle
Sucrose
ConA
# ##
Con-KD CHC-KD Cav1-KD
Fig. 3. Effects of sucrose and ConA on the internalization of several GPCRs. (A–B) Effects of sucro
cells expressingβ2AR (A) or D2R (B*)were treatedwith 0.45M sucrose or 250 μg/ml ConA for 2
and 0.001, respectively, compared to the vehicle-treated group. ##, ###: p b 0.01 and 0.001, res
sucrose on the internalization of the D4 receptor. Cells expressing FLAG-tagged D4Rwith 7 repea
sucrose or ConA, followed by treatment with 10 μMDA for 1 h. Receptor internalization was de
group. #, ##: p b 0.05 and 0.01 compared to Con-KD/vehicle-treated group (n = 5).described previously [6,21]. The FLAG-tagged rat angiotensin II type
1A receptor (AT1AR) was prepared by PCR ampliﬁcation.2.4. Receptor internalization assays
Internalization of D2R and β2AR was determined based on the hydro-
philic properties of [3H]-sulpiride and [3H]-CGP-12177 [14,22]. HEK-293
cells expressing D2R or β2AR were seeded (1.5 × 105 cells/well) 1 day
after transfection in 24-well plates. The following day, the cells were
rinsed once and pre-incubated for 15 min with 0.5 ml pre-warmed
serum-free medium containing 10 mM HEPES (pH 7.4) at 37 °C. The
cells were stimulated with 10 μMDA or 1 μM ISO for 20–60 min, as indi-
cated. The cells were then incubated with 250 μl of [3H]-sulpiride for D2R
(2.2 nM) or [3H]-CGP-12177 for β2AR (10 nM) at 4 °C for 150 min in the
presence or absence of unlabeled competitive inhibitor (10 μM haloperi-
dol or propranolol). The cells werewashed thricewith the samemedium,
and 1% SDSwas added. Samples weremixedwith 2ml Lefkoﬂuor scintil-
lation ﬂuid and counted on a liquid scintillation analyzer.
Internalization of FLAG-tagged D3R, D4R, and AT1ARwas determined
by enzyme-linked immunosorbent assay (ELISA). Cells expressing
FLAG-tagged receptors were treated with 10 μM DA for 1 h or 1 μM
angiotensin II between 30–60 min, respectively. After washing the
cells with serum-free medium, cells were incubated with anti-FLAG
antibodies (1:1000 dilutions) for 1 h at 4 °C. After washing, cells wereB D2R
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2105S. Guo et al. / Biochimica et Biophysica Acta 1848 (2015) 2101–2110ﬁxed with 4% paraformaldehyde in PBS for 15 min on ice, washed, and
treated with horseradish peroxidase-conjugated anti-mouse antibodies
(1:1000 dilutions) for 1 h at room temperature. After washing, cells
were incubated with o-phenylenediamine in PBS, and optical density
was measured at 492 nm.
2.5. Whole cell cAMP assays
Cellular cAMP was measured using an indirect reporter gene meth-
od [23,24]. A reporter plasmid containing the ﬁreﬂy luciferase gene
under the control of multiple cAMP response elements and with the
pRL-TK control vector was utilized. Transfected cells were seeded in
24-well plates, and divided into three identical groups. For the D2, D3,
and D4 receptor, cells were treated with 2 μM forskolin and quinpirole
(10−12–10−8 M) for 4 h before harvesting. The relative luciferase
expression was measured using the dual luciferase assay kit (Promega,
Madison,WI, USA). For β2AR, cells were treatedwith increasing concen-
trations of isoproterenol.
2.6. Confocal microscopy
One day after transfection, the cells were seeded onto coverslips
coated with poly-L-lysine and allowed to recover for one day. To exam-
ine the endocytosis of GFP-tagged receptors, cells were treated withA
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Fig. 4.Determination of ConA-induced changes in the agonist afﬁnity of D2R and D3R, and possi
ConA on the agonist afﬁnity of D2R. Cells expressing 1.1 pmol/mg protein D2R were labeled wit
termined in the presence of 10 μMhaloperidol. Cells were washed thrice, and the remaining rad
agonist afﬁnity of D3R. Cells expressing 1.1 pmol/mg proteinD3Rwere labeledwith 7.2.nM [3H]-
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the effects of ConA on D2R signaling. Cells expressingWT-D2R or a mutant of D2R (0.6–0.7 pmo
with increasing concentrations of quinpirole. ***: p b 0.001 whenWT/ConA and GlyX/ConA gro
group was compared to GlyX/vehicle group (n = 6).agonists and were examined with a laser scanning confocal microscope
(TCS SP5/AOBS/Tandem, Leica, Germany).2.7. Synthesis of Pitstop2™
Pitstop2™ (N-[5-(4-bromobenzylidene)-4-oxo-4,5-dihydrothiazol-
2-yl]naphthalene-1-sulfonamide) was synthesized in two steps from
naphthalene-1-sulfonyl chloride. First, sulfonyl chloride was treated
with 2-aminothiazol-4(5H)-one in the presence of triethylamine to
obtain N-(4-oxo-4,5-dihydrothiazol-2-yl)naphthalene-1-sulfonamide
with a 68% yield. Second, the sulfonamide intermediate was condensed
with 4-bromobenzaldehyde under buffered acidic condition to yield
Pitstop2™ with a 49% yield. A more detailed protocol is described in
the Supplemental data.2.8. Statistics
All results are expressed as the mean ± SEM. Dose response curves
with more than three experimental groups were compared via two-
way analysis of variance (ANOVA) with Bonferroni post-tests. The
Student's t-test was used for some results. A p-value less than 0.05
was considered signiﬁcant.-13 -12 -11 -10 -9 -8 -7
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3.1. Knockdown of CHC and Cav1 abolishes clathrin-dependent and
caveolar endocytosis, respectively
HEK-293 cells inwhich endogenous CHCor Cav1was knocked down
(Fig. 1A and B, lower panel) were employed to determine the selectivity
of clathrin- and caveolae-mediated endocytosis inhibitors. As shown in
the upper panels of Fig. 1A and B, β2ARs were expressed on the plasma
membrane of both CHC-KD and Cav1-KD cells.β2ARs underwent robust
internalization in endocytic vesicles in control cells; however, endocy-
tosis decreased in both theCHC-KDcells (approximately 40% inhibition)
and Cav1-KD cells (approximately 40% inhibition).
GPCRs are classiﬁed into class A and class B, depending on their
endocytic properties [2]. Class A GPCRs, such as β2AR and D2R, show a
transient interaction with β-arrestin and dissociate from β-arrestin
when they enter the cytosol as endocytic vesicles. Class B GPCRs, such
as AT1A receptor and vasopressin type 2 receptor, establish a stable
interaction with β-arrestin when they are internalized in the vesicles.
To test whether class B GPCRs also undergo endocytosis through
clathrin-mediated and caveolar endocytosis, the internalization of the
AT1A receptor was tested in CHC-KD and Cav1-KD cells. As shown in
Fig. S1A, AT1A receptors underwent an extensive internalization, com-
pared to D2R. Approximately 50% of AT1A receptors were internalized
via the clathrin-mediated endocytic route, and 30% were internalized
through the caveolar endocytic route.A
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Cells expressing D2R (1.1 pmol/mg protein) were treated with 20 μM Pitstop2™ for 20 min (nA dominant negative epsin mutant and MβCD were employed to
evaluate whether CME and the caveolar pathway was abolished in
CHC- and Cav1-KD cells. Epsins, which are clathrin-associated sorting
proteins, contribute to CME by binding phospholipids, clathrin, and
the AP2 complex [25]. MβCD is known to disrupt lipid rafts by removing
cholesterol from the plasma membrane [26].
Epsin (204–458) inhibited the internalization of β2AR and D2R in
Con-KD and Cav1-KD cells, but failed to inhibit internalization in
CHC-KD cells (Figs. 2A and S1B), suggesting that CME of the two
receptors was abolished in CHC-KD cells. Dynamin, a GTPase, is
involved in the scission of newly formed vesicles from the parent
membrane, and mediates both clathrin-mediated and caveolar
endocytosis [14,21,27,28]. As shown in Fig. 2A, a dominant negative
mutant of dynamin 2 (K44A-Dyn2) inhibited the internalization of
β2AR in all three cell lines. Virtually the same results were obtained
with D2R (Fig. S1B). The endocytosis of the class B GPCR AT1AR was
also inhibited by sucrose treatment or co-expression of K44A-Dyn2
(Fig. S1C). These results suggest that both clathrin-mediated and
caveolar endocytic pathways are involved in the endocytosis of
class A GPCRs such as β2AR and D2R, and class B GPCRs, such as
AT1AR.
To determine the optimal concentration of MβCD that selectively
inhibits caveolar endocytic routes, a dose-response study was conduct-
ed for the endocytosis of β2AR and D2R. As shown in Fig. 2B, 1-2 mM
MβCD failed to inhibit the internalization of β2AR in all cell lines evalu-
ated. At 3 mM, MβCD inhibited the internalization of β2AR in Con-KDB β2AR
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= 6).
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At 5 mM, MβCD inhibited the internalization of β2AR in all three cell
lines. Our results show that approximately 3 mM MβCD can be used
to inhibit caveolar internalization of β2AR. More detailed analysis
showed that 3–3.5 mM MβCD could be used to selectively inhibit
caveolar endocytosis of β2AR in HEK-293 and COS-7 cells (Fig. S1D).
Essentially the same results were obtained using D2R (Fig. S1E).WT-Dyn2
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CME and the caveolar pathway, respectively. Thus, our studies using
β2AR and D2R show that combination of Cav1-KD and epsin (204–
458) or CHC-KD and 3mMMβCD could be utilized for the simultaneous
blockade of clathrin- and caveolae-mediated GPCR endocytosis. Our
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D2R internalization occurs via clathrin/Cav1-independent endocytic
pathways (Figs. 2A and S1B, epsin [204–458]/Cav1-KD; Fig. S1D,
3.5 mM MβCD/CHC-KD; Fig. 2C, epsin[204–458]/3.5 mM MβCD;;
Fig. 2D, CHC-KD/Cav1-KD). However, it is possible that incomplete
blockade of receptor endocytosis may occur owing to incomplete inhi-
bition or partially efﬁcacious inhibitors, rather than existence of a
third, uncharacterized endocytic route.
GRK2 andβ-arrestins are two representative protein families that reg-
ulate GPCR CME. As shown in Fig. 2E,WT-β2AR endocytosis decreased by
approximately 40% when cellular CHC was knocked down. By contrast,
the endocytosis of β2AR-GRK2-KO was not inhibited in CHC-KD cells. In
β2AR-GRK2-KO, the consensus phosphorylation sites for GRK2 (T360,
S364, S396, S401, S407, S411) were mutated [17]. By contrast, MβCD
inhibited the endocytosis of both WT- and β2AR-GRK2-KO (Fig. 2F).
These results implied that GRK2-mediated endocytosis occurred through
CME (Fig. 2E), and that GRK2-independent endocytosis involved the
caveolar endocytic route (Fig. 2F).
3.2. Sucrose and concanavalin A non-selectively block receptor endocytosis
Hypertonic sucrose and concanavalin A (ConA) have been used as
selective inhibitors of CME for someGPCRs [1,29,30]. Similar to observa-
tions using AT1AR (Fig. S1C, sucrose treatment), internalization of β2AR
(Fig. 3A), D2R (Fig. 3B), and D4R (Fig. 3C) was inhibited in all cell lines
following sucrose or ConA treatment, suggesting that sucrose and
ConA non-selectively block the endocytosis of these receptors. D3R
was not evaluated, because D3R undergoes a negligible degree of
agonist-induced endocytosis [5,14].
It is known that GPCR signaling and endocytosis are closely related
[1,24]. Thus, it is important to test whether endocytic inhibitors affect
GPCR signaling. Pretreatment with sucrose did not interfere with β2AR
(Fig. S2A), D2R, D3R (Fig. S2B), or D4R (Fig. S2C) signaling. By contrast,
ConA strongly inhibited β2AR (Fig. S2D), D2R, D3R (Fig. S2E), and D4R
(Fig. S2F) signaling. The inhibitory effect of ConA on GPCR signaling
most likely occurs independently of receptor internalization inhibition
since this was observed in all of the GPCRs we tested, independent of
their endocytic properties.
Further studies were conducted to understand the molecular mech-
anisms involved in ConA-mediated signaling inhibition. First, inhibition
of D2R andD3R signalingwas not caused by a decrease in agonist afﬁnity
(Fig. 4A and B). ConA is known to speciﬁcally bind to glycoproteins [31].Fig. 7. Speciﬁcity of currently used endocytic inhibitors for clathrin- and caveolae-mediated e
speciﬁcally inhibited CME. MβCD was speciﬁc for the caveolar pathway. Sucrose and ConA sho
‘Ago’ represents agonist.Thus, we tested whether ConA inhibits the signaling of these receptors
by binding to glycosylated residues. For this purpose, a mutant of D2R,
D2R-GlyX, in which the potential N-linked glycosylation sites were
mutated [32], was used. As shown in Fig. 4C, the signaling of WT-D2R
and D2R-GlyX was equally inhibited by treatment with ConA, suggest-
ing that glycosylated residues are not the target of ConA for D2R signal-
ing inhibition.
Combined, these results show that sucrose and ConA are general in-
hibitors of GPCR endocytosis. Furthermore, ConA showed non-selective
inhibition of GPCR signaling.
3.3. Selectivity of lowering pH, MDC, and Pitstop2™ on CME of D2R and
β2AR
It has been reported that internalization through clathrin-coated pits
can be blocked by decreasing cytosolic pH [32,33]. As shown in Fig. 5A
(3rd & 5th bar, Con-KD), internalization of D2R was inhibited when
pH was lowered from 7.4 to 5.0, regardless of the salts used (chloride
or acetate). In control cells, epsin (204–458) inhibited the internaliza-
tion of D2R to a similar extent as lowering pH, but did not further inhibit
D2R internalization at a low pH (2nd & 4th bar), suggesting that lower-
ing pH selectively inhibited CME. The same results were obtained using
COS-7 cells (Fig. S3A). In agreementwith these results, neither lowering
pH nor introduction of epsin (204–458) inhibited the internalization of
D2R when cellular clathrin was knocked down (Fig. 5A, CHC-KD).
MDC, an inhibitor of tissue transglutaminase, has been used to
block receptor CME, including insulin-like growth factor-I and the
α2 adrenoceptor [34,35]. Transglutaminase is involved in protein
cross-linking [36], which mediates clustering and internalization of
clathrin [29]. MDC inhibited the internalization of β2AR (Fig. 5B, test-
ed up to 250 μM) and D2R (Fig. S3B, tested up to 200 μM) in control
and Cav1-KD cells, but not in CHC-KD cells, suggesting that MDC
selectively blocked CME at these concentrations. MDC was strongly
cytotoxic at 300 μM under our experimental conditions (data not
shown).
Pitstop2™ (N-[5-(4-bromobenzylidene)-4-oxo-4,5-dihydro-1,3-
thiazol-2-yl]naphthalene-1-sulfonamide) is a recently developed CME
inhibitor of transferrin with an IC50 value of 12–15 μM. It was reported
that Pitstop2™ inhibits the association between the terminal domain
of clathrin and amphiphysin [37]. At 20 μM, which is the recommended
concentration for CME inhibition of transferrin and EGF uptake [37],
Pitstop2™ showed marginally stronger inhibitory activities on thendocytosis of β2AR and D2R. A dominant negative epsin mutant, MDC, and lowering pH
wed nonspeciﬁc inhibition of internalization. CME has negative effects on ERK activation.
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(Fig. 5D). At 40 μM, Pitstop2™ also inhibited non-CME internalization
of β2AR (Fig. 5C, 40 μM/CHC-KD). Surface expression of D2R and β2AR
noticeably decreased after treatment with Pitstop2™ (Fig. S3C and D).
Interestingly, Pitstop2™ did not affect the surface expression of D3R,
and the surface expression of R132H-D2R was inhibited to a lesser
extent than WT-D2R (Fig. S3E). It is known that D3R and R132H-D2R
rarely undergo internalization [14,38]. Thus, the effects of Pitstop2™
on the surface expression of β2AR and D2R could be related to their
endocytic properties. These results suggest that Pitstop2™ has only
marginal selectivity toward CME (Fig. 5C), and that more extensive
characterization is required to understand its effects on the receptor en-
docytosis and cell surface expression.
3.4. CME exerts negative effects on the ERK activation
Receptor endocytosis is closely related to the regulation of the
GPCR signaling. For example, previous studies showed that agonist-
induced endocytosis of β2AR and D2R mediates the re-sensitization
of desensitized receptors [1,24]. However, the functional role of
receptor internalization through clathrin-mediated and caveolar
endocytic pathways is not clear.
To understand the functional roles of receptor endocytosis, both
CME and caveolar endocytosis were blocked by co-expression of
K44A-Dyn2. As shown in Fig. 6A, co-expression of K44A-Dyn2 signiﬁ-
cantly increased β2AR-mediated ERK activation. The same results
were obtained with D2R and AT1R (Fig. S4A and B), suggesting that
dynamin-mediated endocytic processes have negative effects on signal-
ing from the receptor to ERK. Co-expression of K44A-Dyn2did not affect
the desensitization of D2R-mediated ERK activation (compare ratio of
“5/W/5” to “5” between WT-Dyn2 group and K44A-Dyn2 group). On
the other hand, co-expression of K44A-Dyn2 did not affect the ERK acti-
vationmediated by D3Rwhich does not undergo agonist-induced endo-
cytosis (Fig. S4C). These results show that receptor endocytosis has
negative effects on ERK activation regardless of its post-endocytic fate.
The effects of sucrose could not be tested, because pretreatment with
sucrose itself induced strong ERK activation (data not shown).
Knockdown of either the CHC or Cav1 (Fig. 6B) enhanced ERK activa-
tion, suggesting that the CHC and Cav1 have negative effects on β2AR-
mediated ERK activation. Co-expression of epsin (204–458) to inhibit
β2AR endocytosis increased ERK activation (Fig. 6C). However, disruption
of caveolae by treatment with 3 mMMβCD, which selectively inhibits
caveolar endocytosis, did not affect ERK activation (Fig. 6D). MβCD no-
ticeably inhibited the internalization of β2AR without inﬂuencing cellular
Cav1 levels (Fig. 1B, lower panel). These results suggest that CME of β2AR
has an inhibitory effect on ERK activation. By contrast, Cav1, rather than
caveolar endocytosis, seems to have inhibitory effects on ERK activation
mediated by β2AR.
4. Discussion
CME is the most extensively characterized endocytic route for
GPCRs. Receptor endocytosis via the caveolae, although less thoroughly
characterized than CME, constitutes a distinct and important endocytic
route for GPCRs. Since molecular biological tools that can selectively
abrogate each endocytic route were not available, various endocytic
inhibitors have been usedwithout clear conﬁrmation of their selectivity.
For example, it was reported that agonist-induced endocytosis of β2AR
and D2R mediates re-sensitization using sucrose-induced inhibition of
internalization [1,24]. However, it was unclear which endocytic route
is involved in re-sensitization, because sucrose is a non-speciﬁc inhibi-
tor of receptor endocytosis. Since the functional role of receptor inter-
nalization through each endocytic route is not yet clear, it is critical to
conﬁrm the selectivity of currently used endocytic inhibitors.
Our results indicate that knockdown of CHC and Cav1 can be used as
experimental systems to evaluate the speciﬁcity of chemicals used toblock CME and caveolae-dependent endocytosis. In the case of CME,
epsin (204–458), which selectively blocks and has speciﬁcity for CME,
failed to inhibit endocytosis of β2AR (Fig. 2A) and D2R (Fig. S1B) in
CHC-KD cells. The selectivity of CHC-KD cells for CMEwas corroborated
in studies using a mutant of β2AR, in which GRK2-mediated phosphor-
ylation sitesweremutated (Fig. 2E). Our resultswere in agreementwith
previous studies showing that GRK2-mediated receptor phosphoryla-
tion is responsible for CME. In the case of the caveolar endocytic path-
way, the validity of Cav1-KD cells was conﬁrmed with MβCD, which is
used to disrupt caveolae. As shown in Figs. 2B and S1D, MβCD failed
to inhibit the endocytosis of β2AR in Cav1-KD cells, so long as the con-
centrationwas properly adjusted, suggesting that the caveolar pathway
is properly abolished in Cav1-KD cells.
Our results show that special care is neededwhenusingpharmacolog-
ical agents that were thought to be selective CME inhibitors. For example,
sucrose and ConA inhibited both CME and other endocytic routes, such as
the caveolar pathway. In addition, ConAnon-speciﬁcally inhibited the sig-
naling of all four GPCRs we tested. MDC showed selectivity toward CME,
but extra care is needed to adjust the doses, so that selective CME inhibi-
tion can be obtained without cellular toxicity.
Pitstop2™was reported to inhibit the endocytosis of the transfer-
rin receptor, which enters cells through clathrin-mediated endocytic
routes by blocking the interactions between the amino terminal do-
main of the CHC and amphiphysin [37]. However, a recent study
showed that Pitstop2™ also inhibits clathrin-independent endocyto-
sis [2]. Our results also showed that Pitstop2™ is only marginally se-
lective for CME (Fig. 5C). Thus, even though Pitstop2™ was thought
to be a selective inhibitor of CME, given that Pitstop2™ inhibited
the endocytosis of the transferrin receptor without affecting shiga
toxin endocytosis [37], which enters cells independently of clathrin
[8], Pitstop2™ requires more extensive characterization to guaran-
tee its selectivity. Our results indicate that Pitstop2™ inhibited
both surface expression and internalization of D2R and β2AR, and it
could be speculated that Pitstop2™ affects both agonist-induced en-
docytosis and constitutive recycling of internalized receptors back to
plasma membrane. D2R and β2AR might have a different propensity
to undergo intracellular trafﬁcking to the cytosol and recycling.
Previous studies reported conﬂicting results regarding the role of
receptor endocytosis in ERKactivation by someGPCRs [29,35,39]. A sub-
sequent study suggested that endocytosis of trans-activated EGFR is
required for ERK activation by agonist-activated GPCRs [35]. In this
sense, our results that show K44A-Dyn2 increases ERK activation that
is mediated by endocytosable GPCRs are the ﬁrst observation. In agree-
ment with our results, a more recent study conducted in HeLa cells
showed that knockdown of clathrin heavy chain increased EGF-
induced ERK activation [40], suggesting that CME might have neg-
ative effects on EGFR-mediated ERK activation. It is not clear what
causes such contradictory results among different studies at this
point but the complexity of signaling pathways that lead from
GPCRs to ERK has been emphasized [41,42]. Our results using
Cav1-KD cells and MβCD-treated cells suggest that it might be
Cav1, rather than endocytosis through caveolae, which negatively
regulates β2AR-mediated ERK activation. Previous studies showed
that Cav1 negatively regulates ERK activation [43]. Thus, our re-
sults overall suggest that β2AR and D2R CME negatively regulate
ERK activation.
Fig. 7 summarizes the conclusions of this study. The dominant nega-
tive epsin mutant, MDC, and decreased pH speciﬁcally inhibited CME.
MβCDwas speciﬁc for the caveolar pathway. Sucrose and ConA showed
nonspeciﬁc inhibition of internalization. The CME pathway may be
involved in the inhibition of β2AR- and D2R-mediated ERK activation.
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